European Medicines Agency has endorsed joint statement on prioritisation of COVID-19 clinical trials published by the International Coalition of Medicines Regulatory Authorities (ICMRA)

Medicines regulators around the world have jointly developed this statement which describe key characteristics of clinical trials that are most likely to generate the conclusive evidence needed to enable accelerated approval of potential treatments and vaccines against COVID-19.


European Medicines Agency